Immuno-modulatory progenitor (imp) cell

Abstract

The invention relates to immuno-modulatory progenitor (IMP) cells and their use in therapy.

1 . An isolated population of immuno-modulatory progenitor (IMP) cells, wherein the IMP cells express detectable levels of MIC A/B, CD304 (Neuropilin 1), CD178 (FAS ligand), CD289 (Toll-like receptor 9), CD363 (Sphingosine-1-phosphate receptor 1), CD99, CD181 (C-X-C chemokine receptor type 1; CXCR1), epidermal growth factor receptor (EGF-R), CXCR2, CD126, and HLA-ABC, and wherein at least 80% of the population comprises the IMP cells. 
     
     
         2 . An IMP cell population according to  claim 1 , wherein the population comprises at least about 5×10 5  cells. 
     
     
         3 . An IMP cell population according to  claim 1 , wherein at least 85% of the population comprises the IMP cells. 
     
     
         4 . An IMP cell population according to  claim 1 , wherein at least 90% of the population comprises the IMP cells. 
     
     
         5 . An IMP cell population according to  claim 1 , wherein at least 97% of the population comprises the IMP cells. 
     
     
         6 . An IMP cell population according to  claim 1 , wherein at least 98% of the population comprises the IMP cells. 
     
     
         7 . An IMP cell population according to  claim 1 , wherein at least 99% of the population comprises the IMP cells. 
     
     
         8 . An IMP cell population according to  claim 1 , wherein the IMP cells secrete detectable levels of one or more of interleukin-6 (IL-6), IL-8, C-X-C motif chemokine 10 (CXCL10; interferon gamma-induced protein 10; IP-10), Chemokine (C—C motif) ligand 2 (CCL2; monocyte chemotactic protein-1; MCP-1) and Chemokine (C—C motif) ligand 5 (CCL5; regulated on activation, normal T cell expressed and secreted; RANTES). 
     
     
         9 . A pharmaceutical composition comprising (a) a population according to  claim 1  and (b) a pharmaceutically acceptable carrier or diluent